Enhancing clinical trial safety is paramount, and the recent shift towards Risk-Based Monitoring (RBM) represents a significant advancement in this realm. RBM is a strategic approach that focuses on identifying and mitigating risks throughout the lifecycle of a clinical trial. It emphasizes the importance of a dynamic, data-driven process that…

Marginalized communities face a myriad of health challenges that are often exacerbated by systemic disparities and a lack of access to quality healthcare. Addressing these issues requires a multifaceted approach, from understanding the root causes of health inequities to implementing innovative solutions that cater to the unique needs of these…

Clinical trials are essential for advancing medical science and ensuring that new treatments are safe and effective. However, the importance of diversity in these trials cannot be overstated. A diverse participant base ensures that research outcomes are applicable to the wider population, which is critical when considering the push towards…

Although DEI efforts have ramped up, the industry is still searching for proven ways to get results. By: Alexandra Pecci • Published June 28, 2023 Court Horncastle, senior vice president and business unit head of the anti-infective and respiratory team at GSK in the United States, understands the incredible value of…

Genentech’s chief diversity officer Quita Highsmith is on a crusade to prove that much of what the industry believes about clinical trial diversity is wrong. By: Michael Gibney • Published Dec. 14, 2023 Among the many falsehoods surrounding diversity in clinical trials, the notion that people of color simply don’t want…

Johnson & Johnson Innovative Medicine’s director of diversity, equity and inclusion in clinical trials shares key strategies for making DEI work. By: Alexandra Pecci • Published Nov. 14, 2023 The need for diversity in clinical trials has come to an inflection point, with the FDA issuing draft guidance for how trial sponsors can…